APA

Ramautarsing R. A., van der Lugt J., Gorowara M., Wongsabut J., Khongpetch C., Phanuphak P., Ananworanich J., Lange J. M. A., Burger D. M., Ruxrungtham K. & Avihingsanon A. (20120202). Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily. : Journal of acquired immune deficiency syndromes (1999).

Chicago

Ramautarsing Reshmie A, van der Lugt Jasper, Gorowara Meena, Wongsabut Jiratchaya, Khongpetch Chuleeporn, Phanuphak Praphan, Ananworanich Jintanat, Lange Joep M A, Burger David M, Ruxrungtham Kiat and Avihingsanon Anchalee. 20120202. Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily. : Journal of acquired immune deficiency syndromes (1999).

Harvard

Ramautarsing R. A., van der Lugt J., Gorowara M., Wongsabut J., Khongpetch C., Phanuphak P., Ananworanich J., Lange J. M. A., Burger D. M., Ruxrungtham K. and Avihingsanon A. (20120202). Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily. : Journal of acquired immune deficiency syndromes (1999).

MLA

Ramautarsing Reshmie A, van der Lugt Jasper, Gorowara Meena, Wongsabut Jiratchaya, Khongpetch Chuleeporn, Phanuphak Praphan, Ananworanich Jintanat, Lange Joep M A, Burger David M, Ruxrungtham Kiat and Avihingsanon Anchalee. Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily. : Journal of acquired immune deficiency syndromes (1999). 20120202.